Jae-Lyun Lee

Putative Biomarkers of Clinical Benefit With Pembrolizumab in Advanced Urothelial Cancer: Results From the KEYNOTE-045 and KEYNOTE-052 Landmark Trials.

J. Lunceford, S. Culine, T. Powles, 2022, Clinical cancer research : an official journal of the American Association for Cancer Research.

Predictive biomarkers for survival benefit with ramucirumab in urothelial cancer in the RANGE trial

T. Powles, H. Nishiyama, C. Sternberg, 2022, Nature Communications.

Concordance between Response Assessment Using Prostate-Specific Membrane Antigen PET and Serum Prostate-Specific Antigen Levels after Systemic Treatment in Patients with Metastatic Castration Resistant Prostate Cancer: A Systematic Review and Meta-Analysis

H. Vargas, H. Schoder, A. Wibmer, 2021, Diagnostics.

Xaluritamig, a STEAP1 × CD3 XmAb 2+1 Immune Therapy for Metastatic Castration-Resistant Prostate Cancer: Results from Dose Exploration in a First-in-Human Study

D. Danila, L. Appleman, H. L. Penny, 2023, Cancer discovery.

IFITM3-mediated activation of TRAF6/MAPK/AP-1 pathways induces acquired TKI resistance in clear cell renal cell carcinoma

Hyein Ju, H. Go, Ja-Min Park, 2023, Investigative and clinical urology.